Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Metropolis Healthcare Finalises Acquisition of Ambika Pathology for Rs 17 Crore
This purchase marks Metropolis’ fourth acquisition in the past ten months, following earlier deals involving Dr Ahuja’s Pathology in Dehradun, Scientific Pathology in Agra, and Core Diagnostics in the Delhi NCR region.
- By Newsdesk
- New Delhi
- Sep 20, 2025
Metropolis Healthcare has announced the successful purchase of Ambika Pathology Laboratory, based in Kolhapur, for ₹17 crore. The deal, structured as a slump sale, was agreed with the laboratory’s sole proprietor, Dr. Rajendra Sadashiv Patil. Of the total price, ₹1.7 crore will be paid as deferred consideration, with the balance settled in cash.
Ambika Pathology is NABL-accredited and operates a network of 12 patient collection centres. It draws about three-quarters of its revenue from direct walk-in customers. Over the past three financial years, its turnover has gradually increased: approximately ₹6.7 crore in FY23, ₹7.1 crore in FY24, and about ₹7.96 crore in FY25.
Ameera Shah, Metropolis’ promoter and Executive Chairperson, said the acquisition strengthens the company’s presence in Western Maharashtra, where nearly 40% of its revenue originates. She explained that Ambika Pathology fits naturally into Metropolis’ strategy of building regional clusters under its “String of Pearls” growth model.
This purchase marks Metropolis’ fourth acquisition in the past ten months, following earlier deals involving Dr Ahuja’s Pathology in Dehradun, Scientific Pathology in Agra, and Core Diagnostics in the Delhi NCR region.